Are You Applying the Latest Guidelines for Multiple Myeloma? Experts Discuss Equitable, Evidence-Based Care

The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with multiple myeloma.

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Target Audience

This program is intended for hematologists, oncologists, PAs, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Initiate timely systemic treatment for appropriate patients based on risk assessment and the latest multiple myeloma diagnostic and staging criteria
  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data as well as NCCN guidelines, risk assessment, comorbidities, and patient age/fitness and preferences
  • Select optimal therapies for patients with heavily pretreated relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as NCCN guideline recommendations, and response to and tolerance of previous therapies
  • Appraise the efficacy and safety evidence of novel therapeutics and emerging combination regimens for patients with multiple myeloma
  • Identify patients with relapsed/refractory multiple myeloma who would be eligible for enrollment on key ongoing clinical trials
Additional information
Supporters: 

This educational activity is supported by an independent medical education grant from GSK and an educational grant from Sanofi.

Course summary
Available credit: 
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ABIM Medical Knowledge
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.50 Participation
Course opens: 
01/31/2025
Course expires: 
01/31/2026
Cost:
$0.00

Jens Hillengass, MD, PhD
Professor of Oncology
Chief of Myeloma
Vice Chair of Research 
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Carol Ann Huff, MD
Medical Director, Sidney Kimmel Comprehensive Cancer Center
Associate Professor of Oncology and Medicine
Multiple Myeloma Program
Johns Hopkins University School of Medicine
Baltimore, Maryland

Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Jens Hillengass, MD, PhD
Angitia Biopharmaceuticals: Consultant/Advisor/Speaker 
BeiGene: Consultant/Advisor/Speaker  
Janssen Pharmaceutica Products, LP: Consultant/Advisor/Speaker 
Prothena: Consultant/Advisor/Speaker 
Regeneron Pharmaceuticals, Inc.: Consultant/Advisor/Speaker 
Sebia Inc.: Consultant/Advisor/Speaker

Carol Ann Huff, MD
Janssen Pharmaceutica Products, LP: Consultant/Advisor/Speaker 
Legend Biotech: Consultant/Advisor/Speaker 
Sanofi: Consultant/Advisor/Speaker 

Shaji K. Kumar, MD
AbbVie, Inc.: Consultant/Advisor/Speaker;  Grant/Research Support
Amgen Inc.: Consultant/Advisor/Speaker;  Grant/Research Support
Arcellx, Inc.: Consultant/Advisor/Speaker
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BD Biosciences: Consultant/Advisor/Speaker
BeiGene: Consultant/Advisor/Speaker
Bristol Myers Squibb: Consultant/Advisor/Speaker; Grant/Research Support
CARsgen Therapeutics: Consultant/Advisor/Speaker; Grant/Research Support
GSK: Consultant/Advisor/Speaker; Grant/Research Support
Gracell Biotechnologies Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Consultant/Advisor/Speaker; Grant/Research Support
K36 Therapeutics: Consultant/Advisor/Speaker
Moderna, Inc.: Consultant/Advisor/Speaker
Oricell Therapeutics: Grant/Research Support
Pfizer Inc.: Consultant/Advisor/Speaker
Regeneron Pharmaceuticals, Inc.: Consultant/Advisor/Speaker
Roche/Genentech: Consultant/Advisor/Speaker; Grant/Research Support
Sanofi: Consultant/Advisor/Speaker; Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consultant/Advisor/Speaker; Grant/Research Support
Telo Genomics Corp.: Grant/Research Support

NCCN and CCO Staff Disclosures

None of the planners or content peer reviewers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.5 contact hours. This program offers 1.0 pharmacotherapeutic contact hours for nurses.

Pharmacists
NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-25-025-H01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until January 31, 2026. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to ABIM via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

Available Credit

  • 1.50 AAPA Category 1 CME credit
  • 1.50 ABIM Medical Knowledge
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing